关于我国生物医药企业防范风险实现海外并购价值的建议  

Suggestions on Risk Management and Value Realization of China’s Overseas Biomedical Enterprises’ M&A

作　　者：孙宝刚 钱聪 SUN Baogang;QIAN Cong(Center of Investment Management,China National Biotec Group Company Limited,Beijing 100024,China;Department of Development&Innovation,Zhong’an Online P&C Insurance Co.Ltd.,Beijing 100034,China)

机构地区：[1]中国生物技术股份有限公司投资管理中心,北京100024 [2]众安在线财产保险股份有限公司发展创新部,北京100034

出　　处：《中国卫生标准管理》2022年第19期79-84,共6页China Health Standard Management

摘　　要：生物医药是生物技术与医药行业相结合形成的跨学科综合领域,是当前国际科学前沿最活跃的领域之一,是保障国家安全、国民健康、生物安全的基石。近年来,随着产业政策的支持以及市场需求增加,我国生物医药产业市场规模快速扩张,但相较于欧美我国生物医药产业仍然存在差距。为助力中国生物医药产业跨越式发展,文章分析了生物医药企业海外并购现状、并购动因,并重点对生物医药企业跨国并购过程中面临的风险进行分析,最后对我国生物医药企业有效通过海外并购促进企业发展提出建议。Biomedicine is an interdisciplinary comprehensive field formed by the combination of biotechnology and pharmaceutical industry.It is one of the most active fields of the international science and the cornerstone ensuring the national security,health and biosafety.In recent years,with the support of industrial policies and the increase of market demand,the market scale of China’s biomedical industry has expanded rapidly,but there is still a gap between China and developed countries.In order to promote the leapfrog development of China’s biomedical industry,this paper analyzes the current situation and motivation of overseas M&A of biomedical enterprises,focuses on the risks faced by biomedical enterprises in the process of cross-border M&A,and puts forward some suggestions for China’s biomedical enterprises to effectively promote the development of enterprises through overseas M&A.

关 键 词：生物医药 海外并购 并购动因 并购风险 发展战略 产业协同 

分 类 号：F426[经济管理—产业经济]